View Item 

Show simple item record

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

dc.contributor.authorBorges, Silvanaen_US
dc.contributor.authorDesta, Zeruesenayen_US
dc.contributor.authorLi, Langen_US
dc.contributor.authorSkaar, Todd Cen_US
dc.contributor.authorWard, Bryan Aen_US
dc.contributor.authorNguyen, Anneen_US
dc.contributor.authorJin, Yanen_US
dc.contributor.authorStorniolo, Anna Mariaen_US
dc.contributor.authorNikoloff, D Micheleen_US
dc.contributor.authorWu, Linen_US
dc.contributor.authorHillman, Granten_US
dc.contributor.authorHayes, Daniel Fen_US
dc.contributor.authorStearns, Vereden_US
dc.contributor.authorFlockhart, David Aen_US
dc.date.accessioned2015-01-07T15:23:39Z
dc.date.available2015-01-07T15:23:39Z
dc.date.issued2006-07en_US
dc.identifier.citationBorges, Silvana; Desta, Zeruesenay; Li, Lang; Skaar, Todd C; Ward, Bryan A; Nguyen, Anne; Jin, Yan; Storniolo, Anna Maria; Nikoloff, D Michele; Wu, Lin; Hillman, Grant; Hayes, Daniel F; Stearns, Vered; Flockhart, David A (2006). "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clinical Pharmacology & Therapeutics 80(1): 61-74.en_US
dc.identifier.issn0009-9236en_US
dc.identifier.issn1532-6535en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/109898
dc.publisherJohn Wiley 88 Sonsen_US
dc.titleQuantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatmenten_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/109898/1/cptclpt2006384.pdf
dc.identifier.doi10.1016/j.clpt.2006.03.013en_US
dc.identifier.sourceClinical Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceCandiotti K. A., Birnbach D. J., Lubarsky D. A., Nhuch F., Kamat A. and Koch W. H., et al. ( 2005 ). The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis ?. Anesthesiology 102: 543 – 549.en_US
dc.identifier.citedreferenceJin Y., Desta Z., Stearns V., Ward B., Ho H. and Lee K. H., et al. ( 2005 ). CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97: 30 – 39.en_US
dc.identifier.citedreferenceGoetz M. P., Rae J. M., Suman V. J., Safgren S. L., Ames M. M. and Visscher D. W., et al. ( 2005 ). Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23: 9312 – 9318.en_US
dc.identifier.citedreferenceHou Z. Y., Pickle L. W., Meyer P. S. and Woosley R. L. ( 1991 ). Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 49: 410 – 419.en_US
dc.identifier.citedreferenceDahl M. L., Johansson I., Palmertz M. P., Ingelman‐Sundberg M. and Sjoqvist F. ( 1992 ). Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51: 12 – 17.en_US
dc.identifier.citedreferenceSachse C., Brockmoller J., Bauer S. and Roots I. ( 1997 ). Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60: 284 – 295.en_US
dc.identifier.citedreferenceHuman Cytochrome P450 (CYP) Allele Nomenclature Committee Web site. Available from: URL: http://www.cypalleles.ki.se/cyp2d6.htm. Accessed Feb 15, 2006.en_US
dc.identifier.citedreferenceZanger U. M., Raimundo S. and Eichelbaum M. ( 2004 ). Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369: 23 – 37.en_US
dc.identifier.citedreferenceLundqvist E., Johansson I. and Ingelman‐Sundberg M. ( 1999 ). Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226: 327 – 338.en_US
dc.identifier.citedreferenceDahl M. L., Johansson I., Bertilsson L., Ingelman‐Sundberg M. and Sjoqvist F. ( 1995 ). Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274: 516 – 520.en_US
dc.identifier.citedreferenceLonning P. E., Lien E. A., Lundgren S. and Kvinnsland S. ( 1992 ). Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 22: 327 – 358.en_US
dc.identifier.citedreferenceAdam H. K., Patterson J. S. and Kemp J. V. ( 1980 ). Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep 64: 761 – 764.en_US
dc.identifier.citedreferenceLee K. H., Ward B. A., Desta Z., Flockhart D. A. and Jones D. R. ( 2003 ). Quantification of tamoxifen and three metabolites in plasma by high‐performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 791: 245 – 253.en_US
dc.identifier.citedreferenceDesta Z., Kerbusch T. and Flockhart D. A. ( 1999 ). Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 65: 10 – 20.en_US
dc.identifier.citedreferenceHersberger M., Marti‐Jaun J., Rentsch K. and Hanseler E. ( 2000 ). Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra‐primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 46 (Pt 1): 1072 – 1077.en_US
dc.identifier.citedreferenceRaimundo S., Toscano C., Klein K., Fischer J., Griese E. U. and Eichelbaum M., et al. ( 2004 ). A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 76: 128 – 138.en_US
dc.identifier.citedreferenceSchork N. J., Allison D. B. and Thiel B. ( 1996 ). Mixture distributions in human genetics research. Stat Methods Med Res 5: 155 – 178.en_US
dc.identifier.citedreferenceMcLachlan G. and Peel D. ( 2000 ). In: Finite mixture model. New York: John Wiley 88 Sons; pp. 209 – 210.en_US
dc.identifier.citedreferenceBalding D. J., Bishop M. and Cannings C. ( 2001 ). In: Handbook of statistical genetics. New York: John Wiley 88 Sons; pp. 746 – 747.en_US
dc.identifier.citedreferenceSchwarz G. ( 1978 ). Estimating the dimension of a model. Ann Stat 6: 461 – 464.en_US
dc.identifier.citedreferenceHemeryck A. and Belpaire F. M. ( 2002 ). Selective serotonin reuptake inhibitors and cytochrome P‐450 mediated drug‐drug interactions: an update. Curr Drug Metab 3: 13 – 37.en_US
dc.identifier.citedreferenceBarton D. L., Loprinzi C. L., Novotny P., Shanafelt T., Sloan J. and Wahner‐Roedler D., et al. ( 2003 ). Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 1: 47 – 51.en_US
dc.identifier.citedreferencePlouffe L. Jr, Trott E. A., Largoza M. and Hansen K. A. ( 1997 ). An open trial of sertraline for menopausal hot flushes: potential involvement of serotonin in vasomotor instability. Del Med J 69: 481 – 482.en_US
dc.identifier.citedreferenceStearns V., Beebe K. L., Iyengar M. and Dube E. ( 2003 ). Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289: 2827 – 2834.en_US
dc.identifier.citedreferenceLoprinzi C. L., Sloan J. A., Perez E. A., Quella S. K., Stella P. J. and Mailliard J. A., et al. ( 2002 ). Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20: 1578 – 1583.en_US
dc.identifier.citedreferenceLoprinzi C. L., Kugler J. W., Sloan J. A., Mailliard J. A., LaVasseur B. I. and Barton D. L., et al. ( 2000 ). Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356: 2059 – 2063.en_US
dc.identifier.citedreferenceFisher B., Costantino J. P., Wickerham D. L., Redmond C. K., Kavanah M. and Cronin W. M., et al. ( 1998 ). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P‐1 Study. J Natl Cancer Inst 90: 1371 – 1388.en_US
dc.identifier.citedreferenceOsborne C. K. ( 1998 ). Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609 – 1618.en_US
dc.identifier.citedreferenceDesta Z., Ward B. A., Soukhova N. V. and Flockhart D. A. ( 2004 ). Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310: 1062 – 1075.en_US
dc.identifier.citedreferenceRochat B. ( 2005 ). Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 44: 349 – 366.en_US
dc.identifier.citedreferenceScripture C. D., Sparreboom A. and Figg W. D. ( 2005 ). Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 6: 780 – 789.en_US
dc.identifier.citedreferenceJordan V. C., Collins M. M., Rowsby L. and Prestwich G. ( 1977 ). A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75: 305 – 316.en_US
dc.identifier.citedreferenceStearns V., Johnson M. D., Rae J. M., Morocho A., Novielli A. and Bhargava P., et al. ( 2003 ). Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758 – 1764.en_US
dc.identifier.citedreferenceClarke R., Liu M. C., Bouker K. B., Gu Z., Lee R. Y. and Zhu Y., et al. ( 2003 ). Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316 – 7339.en_US
dc.identifier.citedreferenceLien E. A., Solheim E., Kvinnsland S. and Ueland P. M. ( 1988 ). Identification of 4‐hydroxy‐N‐desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48: 2304 – 2308.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cptclpt2006384.pdf
Size:
524.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.